Index S&P 500 P/E 60.13 EPS (ttm) 5.47 Insider Own 0.20% Shs Outstand 49.10M Perf Week -0.18%
Market Cap 17.60B Forward P/E 26.16 EPS next Y 12.58 Insider Trans -5.54% Shs Float 48.73M Perf Month -5.01%
Income 272.40M PEG 6.01 EPS next Q 3.10 Inst Own 91.60% Short Float 1.37% Perf Quarter 5.31%
Sales 2.44B P/S 7.21 EPS this Y 29.20% Inst Trans 0.65% Short Ratio 2.57 Perf Half Y 3.80%
Book/sh 76.58 P/B 4.30 EPS next Y 31.46% ROA 4.30% Target Price 344.58 Perf Year 5.05%
Cash/sh 2.38 P/C 138.11 EPS next 5Y 10.00% ROE 7.50% 52W Range 236.68 - 371.59 Perf YTD 2.40%
Dividend 0.06 P/FCF 98.57 EPS past 5Y 10.80% ROI 9.70% 52W High -11.46% Beta 0.83
Dividend % 0.02% Quick Ratio 0.60 Sales past 5Y 9.10% Gross Margin 64.10% 52W Low 39.01% ATR 9.39
Employees 12000 Current Ratio 1.20 Sales Q/Q -14.90% Oper. Margin 14.70% RSI (14) 44.93 Volatility 2.46% 2.75%
Optionable Yes Debt/Eq 0.50 EPS Q/Q -53.50% Profit Margin 11.40% Rel Volume 0.98 Prev Close 325.46
Shortable Yes LT Debt/Eq 0.35 Earnings Dec 03 AMC Payout 1.10% Avg Volume 259.15K Price 329.01
Recom 2.40 SMA20 -1.20% SMA50 -3.39% SMA200 5.84% Volume 252,892 Change 1.09%
Jul-06-20 Downgrade Robert W. Baird
Outperform → Neutral
$291
Mar-05-20 Initiated Citigroup
Neutral
$360
Feb-01-19 Upgrade Stephens
Equal-Weight → Overweight
$305
Jan-04-19 Downgrade Goldman
Neutral → Sell
Jul-30-18 Upgrade KeyBanc Capital Mkts
Sector Weight → Overweight
Apr-04-18 Initiated Goldman
Neutral
$231
Dec-08-17 Reiterated Stifel
Buy
$275 → $265
Sep-12-17 Reiterated Stifel
Buy
$265 → $275
Sep-01-17 Reiterated Piper Jaffray
Overweight
$265 → $280
Jul-21-17 Downgrade KeyBanc Capital Mkts
Overweight → Sector Weight
Jun-29-17 Initiated Guggenheim
Neutral
Jun-02-17 Reiterated Stifel
Buy
$220 → $231
Dec-12-16 Upgrade Wells Fargo
Market Perform → Outperform
Sep-02-16 Reiterated BMO Capital Markets
Outperform
$199 → $206
Aug-31-16 Reiterated Stifel
Buy
$195 → $215
Jun-30-16 Reiterated Stifel
Buy
$180 → $195
Jun-03-16 Reiterated Jefferies
Buy
$175 → $190
Apr-15-16 Upgrade Jefferies
Hold → Buy
Dec-17-15 Initiated Goldman
Neutral
Dec-04-15 Downgrade JP Morgan
Overweight → Neutral
Nov-26-20 12:30PM 08:58AM 12:06AM Nov-24-20 08:21AM Nov-12-20 04:15PM Nov-10-20 09:23AM 08:00AM Nov-03-20 04:15PM Oct-27-20 07:59AM Oct-19-20 02:11PM Oct-09-20 08:00AM Oct-03-20 11:30AM Oct-01-20 07:50AM Sep-21-20 03:02PM Investor's Business Daily
06:47AM Sep-14-20 10:02AM Sep-12-20 07:28AM Sep-10-20 07:15AM Sep-08-20 08:33AM Sep-07-20 02:03AM Sep-05-20 10:50AM Sep-04-20 03:50PM Morningstar Research +5.44%
07:29AM 06:31AM Sep-03-20 05:11PM 04:15PM Sep-02-20 10:13AM Aug-31-20 04:15PM 03:01PM 08:15AM Aug-26-20 12:30PM Aug-24-20 11:20AM Aug-19-20 04:15PM Aug-13-20 04:15PM Aug-06-20 04:15PM Aug-05-20 11:40AM Jul-20-20 04:02PM Jul-11-20 03:46PM Jul-09-20 04:15PM Jul-06-20 04:15PM Jul-02-20 09:34AM Jun-30-20 12:56PM Jun-25-20 08:13AM Jun-15-20 11:11AM Jun-09-20 05:06PM Thomson Reuters StreetEvents -5.33%
Jun-05-20 12:02PM 10:42AM 01:00AM Jun-04-20 05:35PM 04:15PM 03:00PM Jun-01-20 09:52AM May-28-20 01:33PM 12:30PM May-14-20 07:30AM May-07-20 04:15PM Apr-21-20 02:02PM Apr-13-20 09:45AM 09:42AM Apr-09-20 07:28AM Apr-04-20 11:30AM Apr-03-20 11:40AM Apr-01-20 04:15PM Mar-30-20 06:32AM Mar-18-20 11:40AM Mar-17-20 09:20PM Mar-13-20 09:49AM Mar-09-20 06:55PM Thomson Reuters StreetEvents
12:03PM Investor's Business Daily
Mar-06-20 09:53AM Mar-05-20 05:35PM 04:15PM 03:00PM Mar-03-20 09:26AM Feb-27-20 01:04PM Investor's Business Daily
12:30PM Feb-26-20 12:10PM Feb-24-20 09:36AM Feb-18-20 04:15PM Feb-12-20 04:15PM Feb-11-20 04:15PM Feb-07-20 04:15PM Feb-04-20 04:15PM Jan-29-20 06:32AM Jan-09-20 04:20PM 12:27PM Jan-07-20 04:15PM Jan-04-20 11:30AM Jan-03-20 07:13AM Dec-19-19 04:15PM Dec-12-19 12:03AM Thomson Reuters StreetEvents
Dec-09-19 04:15PM Dec-08-19 08:29AM Dec-06-19 08:21AM Dec-05-19 05:35PM 04:15PM 03:44PM Dec-03-19 08:24AM 07:25AM Dec-02-19 09:40AM
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services focusing on women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive option, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, and distributors. The Cooper Companies, Inc. was founded in 1980 and is based in San Ramon, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Auerbach Robert D Special Advisor to the CEO Oct 08 Sale 350.00 2,538 888,300 1,403 Oct 09 08:26 PM PETERSMEYER GARY S Director Oct 06 Option Exercise 162.69 1,000 162,690 2,338 Oct 07 05:06 PM PETERSMEYER GARY S Director Oct 06 Sale 348.54 1,000 348,540 1,338 Oct 07 05:06 PM Lindell Jody S Director Sep 16 Option Exercise 66.80 6,500 434,200 19,054 Sep 17 05:21 PM Lindell Jody S Director Sep 16 Sale 338.69 6,500 2,201,453 12,554 Sep 17 05:21 PM White Albert G III President & CEO Jul 08 Buy 278.23 1,000 278,230 41,430 Jul 08 04:58 PM Sheffield Holly R EVP, CSO Jul 08 Buy 280.20 534 149,624 1,414 Jul 08 04:57 PM Sheffield Holly R EVP, CSO Jul 08 Buy 280.00 355 99,400 1,285 Jul 08 04:57 PM Ricupati Agostino SVP, Fin & Tax; Chief Actg Off Jul 01 Option Exercise 0.00 348 0 2,148 Jul 02 05:45 PM Sheffield Holly R EVP, CSO Jun 12 Buy 283.18 880 249,198 880 Jun 15 04:43 PM Ricupati Agostino SVP, Fin & Tax; Chief Actg Off Jun 11 Buy 281.47 1,000 281,470 1,800 Jun 15 04:39 PM Sheffield Holly R EVP, CSO Jun 04 Option Exercise 0.00 1,105 0 1,383 Jun 08 04:30 PM Ricupati Agostino SVP, Fin & Tax; Chief Actg Off Feb 03 Option Exercise 0.00 555 0 1,057 Feb 04 04:59 PM Golden Randal VP, General Counsel & Sec. Feb 03 Option Exercise 0.00 610 0 1,995 Feb 04 04:58 PM Auerbach Robert D President, CSI Feb 03 Option Exercise 0.00 666 0 4,582 Feb 04 04:47 PM Andrews Brian G SVP, CFO & Treasurer Feb 03 Option Exercise 0.00 555 0 1,935 Feb 04 04:46 PM Auerbach Robert D President, CSI Jan 08 Option Exercise 0.00 1,907 0 3,723 Jan 10 06:15 PM Ricupati Agostino SVP, Fin & Tax; Chief Actg Off Jan 08 Option Exercise 0.00 1,065 0 637 Jan 10 06:15 PM Andrews Brian G SVP, CFO & Treasurer Jan 08 Option Exercise 0.00 595 0 1,438 Jan 10 06:12 PM Golden Randal VP, General Counsel & Sec. Jan 08 Option Exercise 0.00 502 0 1,520 Jan 10 06:13 PM Sheffield Holly R EVP, CSO Jan 08 Option Exercise 0.00 589 0 589 Jan 10 06:11 PM White Albert G III President & CEO Jan 08 Option Exercise 0.00 452 0 39,454 Jan 10 06:10 PM McBride Daniel G EVP, COO & Pres-CooperVision Jan 08 Option Exercise 0.00 708 0 31,395 Jan 10 06:09 PM Lindell Jody S Director Jan 06 Option Exercise 49.57 3,500 173,495 16,054 Jan 07 04:57 PM Lindell Jody S Director Jan 06 Sale 321.01 3,500 1,123,534 12,554 Jan 07 04:57 PM PETERSMEYER GARY S Director Jan 06 Sale 322.29 250 80,573 1,338 Jan 07 04:54 PM KALKSTEIN MICHAEL Director Jan 02 Option Exercise 61.36 9,500 582,910 12,338 Jan 06 05:44 PM KALKSTEIN MICHAEL Director Jan 02 Sale 320.35 9,500 3,043,319 5,838 Jan 06 05:44 PM
Index - P/E 122.89 EPS (ttm) 0.87 Insider Own 2.10% Shs Outstand 42.80M Perf Week 4.70%
Market Cap 4.44B Forward P/E 34.16 EPS next Y 3.13 Insider Trans -5.16% Shs Float 41.74M Perf Month 24.77%
Income 37.90M PEG 8.19 EPS next Q 0.75 Inst Own - Short Float 7.17% Perf Quarter 56.17%
Sales 891.30M P/S 4.98 EPS this Y 53.50% Inst Trans 1.18% Short Ratio 6.18 Perf Half Y 59.60%
Book/sh 21.46 P/B 4.98 EPS next Y 31.34% ROA 2.80% Target Price 93.25 Perf Year 31.99%
Cash/sh 15.15 P/C 7.05 EPS next 5Y 15.00% ROE 4.30% 52W Range 54.24 - 108.32 Perf YTD 30.68%
Dividend - P/FCF 35.86 EPS past 5Y 11.40% ROI 7.30% 52W High -1.41% Beta 0.99
Dividend % - Quick Ratio 3.70 Sales past 5Y 15.30% Gross Margin 46.60% 52W Low 96.88% ATR 3.30
Employees 2700 Current Ratio 4.10 Sales Q/Q -6.60% Oper. Margin 4.20% RSI (14) 83.70 Volatility 3.10% 3.61%
Optionable Yes Debt/Eq 0.50 EPS Q/Q -56.60% Profit Margin 4.30% Rel Volume 0.70 Prev Close 107.75
Shortable Yes LT Debt/Eq 0.50 Earnings Oct 27 AMC Payout 0.00% Avg Volume 484.38K Price 106.79
Recom 2.10 SMA20 11.07% SMA50 25.55% SMA200 44.57% Volume 338,098 Change -0.89%
Jul-07-20 Initiated Stephens
Overweight
$90
Feb-07-20 Reiterated Dougherty & Company
Buy
$92 → $100
Nov-21-19 Reiterated Dougherty & Company
Buy
$90 → $92
Jul-26-19 Upgrade Craig Hallum
Hold → Buy
$85
Mar-07-19 Reiterated Dougherty & Company
Buy
$78 → $90
Jun-29-18 Resumed The Benchmark Company
Buy
$63
Sep-05-17 Reiterated The Benchmark Company
Buy
$55 → $67
Jul-28-17 Reiterated Dougherty & Company
Buy
$45 → $49
Apr-21-17 Downgrade Piper Jaffray
Overweight → Neutral
Jan-19-17 Initiated Dougherty & Company
Buy
$44
Dec-06-16 Reiterated The Benchmark Company
Buy
$39 → $55
Jul-07-16 Reiterated FBR Capital
Outperform
$35 → $40
Mar-21-16 Reiterated Topeka Capital Markets
Buy
$38 → $37
Jan-07-16 Initiated The Benchmark Company
Buy
$33
Nov-16-15 Reiterated Topeka Capital Markets
Buy
$40 → $38
Oct-30-15 Reiterated FBR Capital
Outperform
$40 → $35
Sep-28-15 Upgrade Sidoti
Neutral → Buy
Jul-31-15 Reiterated Topeka Capital Markets
Buy
$39 → $40
Jul-31-15 Reiterated Oppenheimer
Outperform
$44 → $42
Jun-18-15 Initiated Oppenheimer
Outperform
$44
Nov-12-20 03:55PM Investor's Business Daily
Nov-11-20 08:01AM Nov-10-20 08:01AM Nov-09-20 08:01AM Nov-06-20 05:27PM Nov-03-20 09:14AM Oct-27-20 08:31PM 05:25PM 04:59PM 04:01PM Oct-26-20 10:18AM Oct-22-20 08:01AM Oct-20-20 12:31PM 08:01AM Oct-06-20 12:38PM 11:40AM 08:00AM Oct-01-20 04:01PM Sep-29-20 04:53PM Sep-23-20 11:24AM 06:45AM Sep-22-20 07:00AM Sep-08-20 01:13PM Sep-01-20 04:15PM Aug-27-20 11:31AM Aug-18-20 10:51AM Aug-17-20 09:10AM 08:00AM Aug-12-20 10:02AM 08:00AM Aug-11-20 12:04PM 11:57AM Jul-29-20 09:54AM Jul-28-20 10:01PM 05:33PM 04:01PM Jul-21-20 04:01PM Jul-20-20 08:00AM Jul-16-20 12:32PM Jun-25-20 08:13AM Jun-24-20 10:38AM Jun-11-20 11:40AM Jun-05-20 10:02AM Thomson Reuters StreetEvents +8.02%
May-08-20 10:08AM 03:01AM May-07-20 04:01PM May-01-20 04:05PM Apr-30-20 12:34PM Apr-28-20 04:05PM Apr-16-20 12:31PM Apr-01-20 11:40AM Mar-27-20 10:47AM Mar-16-20 05:57PM Investor's Business Daily -12.47%
11:40AM Mar-12-20 09:17AM Mar-07-20 11:31AM Mar-05-20 08:30AM Feb-19-20 08:06AM Thomson Reuters StreetEvents
Feb-13-20 08:49AM Feb-12-20 11:40AM Feb-10-20 08:00AM Feb-07-20 09:31AM Feb-06-20 05:25PM 04:01PM 02:30PM Feb-03-20 08:01AM Jan-30-20 04:05PM 12:31PM Jan-28-20 10:49AM 08:00AM Jan-26-20 11:00PM Jan-21-20 09:21AM 08:17AM 08:00AM Jan-20-20 07:34AM Jan-16-20 07:01AM Jan-15-20 06:48AM Jan-14-20 08:36AM Jan-13-20 08:39AM Jan-09-20 05:52AM Jan-07-20 11:12AM 10:54AM 10:08AM 09:35AM 09:09AM Jan-06-20 04:24PM 07:53AM Jan-03-20 10:48AM 08:36AM Dec-31-19 10:53AM 10:45AM Dec-30-19 11:47AM 09:31AM 08:44AM Dec-27-19 10:16AM 08:47AM Dec-18-19 08:21AM Dec-17-19 08:22AM 05:00AM Dec-14-19 07:47PM
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LIPPS RANDALL A Chairman, President and CEO Nov 23 Option Exercise 0.00 12,600 0 164,716 Nov 23 06:24 PM LIPPS RANDALL A Chairman, President and CEO Nov 23 Sale 105.40 12,600 1,328,030 152,116 Nov 23 06:24 PM LIPPS RANDALL A Chairman, President and CEO Nov 20 Option Exercise 0.00 2,400 0 154,516 Nov 23 06:24 PM LIPPS RANDALL A Chairman, President and CEO Nov 20 Sale 105.01 2,400 252,034 152,116 Nov 23 06:24 PM LIPPS RANDALL A Chairman, President and CEO Nov 04 Sale 89.59 11,435 1,024,439 229,113 Nov 04 05:48 PM LIPPS RANDALL A Chairman, President and CEO Sep 16 Sale 75.64 13,743 1,039,501 240,548 Sep 16 07:56 PM LIPPS RANDALL A Chairman, President and CEO Sep 15 Sale 75.01 1,400 105,009 254,291 Sep 16 07:56 PM LIPPS RANDALL A Chairman, President and CEO Jul 29 Sale 75.15 3,718 279,398 148,398 Jul 30 12:42 PM Seidelmann Scott Peter EVP, Chief Commercial Officer Jun 16 Sale 67.70 2,125 143,869 31,260 Jun 17 05:09 PM LIPPS RANDALL A Chairman, President and CEO May 14 Option Exercise 60.39 5,500 332,145 162,352 May 14 06:42 PM LIPPS RANDALL A Chairman, President and CEO May 13 Option Exercise 59.36 2,450 145,432 156,852 May 14 06:42 PM LIPPS RANDALL A Chairman, President and CEO Apr 03 Sale 66.11 5,000 330,566 259,409 Apr 03 04:58 PM LIPPS RANDALL A Chairman, President and CEO Apr 02 Sale 62.93 5,000 314,631 264,409 Apr 03 12:13 PM Bauer Joanne B Director Feb 19 Sale 88.42 2,919 258,112 15,916 Feb 19 06:29 PM Kuipers Peter J. Executive V P& CFO Feb 14 Option Exercise 0.00 11,267 0 70,285 Feb 18 02:38 PM Kuipers Peter J. Executive V P& CFO Feb 14 Sale 89.79 11,267 1,011,637 59,018 Feb 18 02:38 PM Seidelmann Scott Peter EVP, Chief Commercial Officer Feb 10 Option Exercise 0.00 2,833 0 26,474 Feb 11 12:16 PM Seidelmann Scott Peter EVP, Chief Commercial Officer Feb 10 Sale 86.37 2,833 244,698 23,641 Feb 11 12:16 PM LIPPS RANDALL A Chairman, President and CEO Jan 07 Option Exercise 0.00 24,000 0 140,466 Jan 08 04:28 PM LIPPS RANDALL A Chairman, President and CEO Jan 07 Sale 81.43 5,000 407,143 284,409 Jan 08 04:28 PM LIPPS RANDALL A Chairman, President and CEO Jan 07 Sale 81.41 24,000 1,953,852 116,466 Jan 08 04:28 PM Seidelmann Scott Peter EVP, Chief Commercial Officer Dec 16 Sale 80.59 1,356 109,281 23,641 Dec 16 04:47 PM JOHNSTON DAN S EVP & Chief Legal & Admin Nov 29 Option Exercise 0.00 6,250 0 34,076 Dec 02 02:31 PM JOHNSTON DAN S EVP & Chief Legal & Admin Nov 29 Sale 80.38 9,086 730,299 24,990 Dec 02 02:31 PM
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
